Aug 01st 2012 - Edison Investment Research today published a report on Hutchison China MediTech (HCM.L, LSE:HCM, LON:HCM) entitled "An Attractive Play On Chinese Healthcare". In summary, the report says:
The attraction of Hutchison China Meditech (Chi-Med) is its exquisite exposure to the Chinese healthcare market, which remains one of the most dynamic in the world. China Healthcare is the largest of three operating divisions within Chi-Med and is well placed to exploit these opportunities. However, we believe it is the progress within the MediPharma R&D unit, with five novel small molecules in early clinical trials, that could lead to a re-rating in the near term.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »